trending Market Intelligence /marketintelligence/en/news-insights/trending/ehdDk3ewzCqOpFGWKbLxhQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

US FDA accepts for review Supernus' application for ADHD drug

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


US FDA accepts for review Supernus' application for ADHD drug

The U.S. Food and Drug Administration accepted for review Supernus Pharmaceuticals Inc.'s application for attention deficit hyperactivity disorder drug SPN-812.

The drug is intended for the treatment of children and adolescents with ADHD. Symptoms of the disorder include difficulty paying attention, being overactive and acting impulsively.

The regulator is expected to make a decision by Nov. 8.

Rockville, Md.-based Supernus' new drug application is backed by data from four phase 3 clinical studies, two mid-stage ones and several phase 1 trials. Results from the studies showed the medication reduced ADHD symptoms such as hyperactivity, impulsive behavior and inattention in children.

The company started another phase 3 trial of SPN-812 in adult ADHD patients in late 2019.

Supernus Pharmaceuticals develops and commercializes products to treat central nervous system diseases in the U.S.